Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis

Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis ChemomAb Therapeutics Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company, has published a research article in JCI Insight that highlights the important role of CCL24 in primary sclerosing cholangitis (PSC). The article includes extensive data showing that Chemomab..